Drugs / TC-N201 cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05881525 | Jun 2023 → Dec 2025 overdue | cancer | TCRCure Biopharma Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TC-N201 cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05881525 ↗ |
| Modality | Cell therapy | “The genetically engineered cells are called NY-ESO-1 TCR-T cells.” NCT05881525 ↗ |